170 related articles for article (PubMed ID: 27714671)
41. Prognostic signature associated with radioresistance in head and neck cancer via transcriptomic and bioinformatic analyses.
You GR; Cheng AJ; Lee LY; Huang YC; Liu H; Chen YJ; Chang JT
BMC Cancer; 2019 Jan; 19(1):64. PubMed ID: 30642292
[TBL] [Abstract][Full Text] [Related]
42. Identification and clinical validation of gene signatures with grade and survival in head and neck carcinomas.
Ma W; Cao Q; She W
Braz J Med Biol Res; 2021; 54(11):e11069. PubMed ID: 34550272
[TBL] [Abstract][Full Text] [Related]
43. Integrative Analysis Identified CD38 As a Key Node That Correlates Highly with Immunophenotype, Chemoradiotherapy Resistance, And Prognosis of Head and Neck Cancer.
He Z; Yue C; Chen X; Li X; Zhang L; Tan S; Yi X; Luo G; Zhou Y
J Cancer; 2023; 14(1):72-87. PubMed ID: 36605482
[TBL] [Abstract][Full Text] [Related]
44. Prognostic value of p53 and MDM2 expression in bilharziasis-associated squamous cell carcinoma of the urinary bladder.
El-Kenawy Ael-M; El-Kott AF; Khalil AM
Int J Biol Markers; 2003; 18(4):284-9. PubMed ID: 14756544
[TBL] [Abstract][Full Text] [Related]
45. Towards neuroimmunotherapy for cancer: the neurotransmitters glutamate, dopamine and GnRH-II augment substantially the ability of T cells of few head and neck cancer patients to perform spontaneous migration, chemotactic migration and migration towards the autologous tumor, and also elevate markedly the expression of CD3zeta and CD3epsilon TCR-associated chains.
Saussez S; Laumbacher B; Chantrain G; Rodriguez A; Gu S; Wank R; Levite M
J Neural Transm (Vienna); 2014 Aug; 121(8):1007-27. PubMed ID: 25030361
[TBL] [Abstract][Full Text] [Related]
46. Saliva Based Liquid Biopsies in Head and Neck Cancer: How Far Are We From the Clinic?
Patel A; Patel S; Patel P; Tanavde V
Front Oncol; 2022; 12():828434. PubMed ID: 35387114
[TBL] [Abstract][Full Text] [Related]
47. Comparison of albumin adjusted ischemia-modified albumin and total antioxidant status in patients with locally advanced head and neck cancer: A pilot study.
Madhumita R; Nanda N; Sethi P; Rani JM; Natarajan C
J Cancer Res Ther; 2022; 18(1):76-80. PubMed ID: 35381765
[TBL] [Abstract][Full Text] [Related]
48. Human papillomavirus, p16 and p53 expression associated with survival of head and neck cancer.
Smith EM; Rubenstein LM; Hoffman H; Haugen TH; Turek LP
Infect Agent Cancer; 2010 Feb; 5():4. PubMed ID: 20181227
[TBL] [Abstract][Full Text] [Related]
49. Prognostic relevance of C-terminal Mdm2 detection is enhanced by p53 positivity in soft tissue sarcomas.
Würl P; Meye A; Berger D; Bache M; Lautenschläger C; Schmidt H; Kalthoff H; Rath FW; Taubert H
Diagn Mol Pathol; 1997 Oct; 6(5):249-54. PubMed ID: 9458382
[TBL] [Abstract][Full Text] [Related]
50. p53 and mdm2 as prognostic indicators in patients with epithelial ovarian cancer: a multivariate analysis.
Dogan E; Saygili U; Tuna B; Gol M; Gürel D; Acar B; Koyuncuoğlu M
Gynecol Oncol; 2005 Apr; 97(1):46-52. PubMed ID: 15790436
[TBL] [Abstract][Full Text] [Related]
51. Pretreatment neutrophil to lymphocyte ratio in determining the prognosis of head and neck cancer: a meta-analysis.
Yu Y; Wang H; Yan A; Wang H; Li X; Liu J; Li W
BMC Cancer; 2018 Apr; 18(1):383. PubMed ID: 29618336
[TBL] [Abstract][Full Text] [Related]
52. Effects of MDM2 promoter polymorphisms and p53 codon 72 polymorphism on risk and age at onset of squamous cell carcinoma of the head and neck.
Yu H; Huang YJ; Liu Z; Wang LE; Li G; Sturgis EM; Johnson DG; Wei Q
Mol Carcinog; 2011 Sep; 50(9):697-706. PubMed ID: 21656578
[TBL] [Abstract][Full Text] [Related]
53. The need for supportive care among head and neck cancer patients: psychometric assessment of the Dutch version of the Supportive Care Needs Survey Short-Form (SCNS-SF34) and the newly developed head and neck cancer module (SCNS-HNC).
Jansen F; Witte BI; van Uden-Kraan CF; Braspenning AM; Leemans CR; Verdonck-de Leeuw IM
Support Care Cancer; 2016 Nov; 24(11):4639-49. PubMed ID: 27318479
[TBL] [Abstract][Full Text] [Related]
54. Expression profile of tumour suppressor protein p53 and its regulator MDM2 in a cohort of breast cancer patients in a Tertiary Hospital in Ghana.
Opoku F; Bedu-Addo K; Titiloye NA; Atta Manu E; Ameh-Mensah C; Duduyemi BM
PLoS One; 2021; 16(10):e0258543. PubMed ID: 34695137
[TBL] [Abstract][Full Text] [Related]
55. Systematic analysis of differentially methylated expressed genes and site-specific methylation as potential prognostic markers in head and neck cancer.
Bai G; Song J; Yuan Y; Chen Z; Tian Y; Yin X; Niu Y; Liu J
J Cell Physiol; 2019 Dec; 234(12):22687-22702. PubMed ID: 31131446
[TBL] [Abstract][Full Text] [Related]
56. [Expression of P21 WAF1/CIP1 in human astrocytomas in correlating with P53, MDM2, and cellular proliferation index].
Xu QZ; Liu F; Lu DH; Yu SZ; Yang H
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2001 Aug; 23(4):341-5. PubMed ID: 12940073
[TBL] [Abstract][Full Text] [Related]
57. Application of circulating tumour cells to predict response to treatment in head and neck cancer.
Zhang X; Ekanayake Weeramange C; Hughes BGM; Vasani S; Liu ZY; Warkiani ME; Hartel G; Ladwa R; Thiery JP; Kenny L; Punyadeera C
Cell Oncol (Dordr); 2022 Aug; 45(4):543-555. PubMed ID: 35737211
[TBL] [Abstract][Full Text] [Related]
58. Predictive value of cell cycle markers p53, MDM2, p21, and Ki-67 in superficial bladder tumor recurrence.
Pfister C; Moore L; Allard P; Larue H; Lacombe L; Têtu B; Meyer F; Fradet Y
Clin Cancer Res; 1999 Dec; 5(12):4079-84. PubMed ID: 10632343
[TBL] [Abstract][Full Text] [Related]
59. Serum anti-MDM2 and anti-c-Myc autoantibodies as biomarkers in the early detection of lung cancer.
Li P; Shi JX; Dai LP; Chai YR; Zhang HF; Kankonde M; Kankonde P; Yu BF; Zhang JY
Oncoimmunology; 2016 May; 5(5):e1138200. PubMed ID: 27467958
[TBL] [Abstract][Full Text] [Related]
60. Alteration of p53 pathway in squamous cell carcinoma of the head and neck: impact on treatment outcome in patients treated with larynx preservation intent.
Osman I; Sherman E; Singh B; Venkatraman E; Zelefsky M; Bosl G; Scher H; Shah J; Shaha A; Kraus D; Cordon-Cardo C; Pfister DG
J Clin Oncol; 2002 Jul; 20(13):2980-7. PubMed ID: 12089228
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
